Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Income (2016 - 2025)

Ironwood Pharmaceuticals' Non Operating Income history spans 16 years, with the latest figure at -$6.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 15.29% year-over-year to -$6.4 million; the TTM value through Dec 2025 reached -$28.5 million, down 1.97%, while the annual FY2025 figure was -$28.5 million, 4549.53% down from the prior year.
  • Non Operating Income for Q4 2025 was -$6.4 million at Ironwood Pharmaceuticals, up from -$7.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.9 million in Q2 2023 and bottomed at -$10.7 million in Q2 2021.
  • The 5-year median for Non Operating Income is -$6.2 million (2024), against an average of -$4.4 million.
  • The largest YoY upside for Non Operating Income was 517.38% in 2023 against a maximum downside of 664.23% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$10.3 million in 2021, then surged by 137.75% to $3.9 million in 2022, then crashed by 285.26% to -$7.2 million in 2023, then dropped by 3.69% to -$7.5 million in 2024, then rose by 15.29% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Non Operating Income are -$6.4 million (Q4 2025), -$7.5 million (Q3 2025), and -$7.5 million (Q2 2025).